Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Danaher (DHR) to $225 from $254 and keeps an Outperform rating on the shares, which were also added to the firm’s “Tactical Outperform” as part of the firm’s medical technology and life science tools Q1 preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Wix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls
- Danaher put volume heavy and directionally bearish
- Palantir upgraded, Workday downgraded: Wall Street’s top analyst calls
- Danaher’s Masimo Acquisition: Strategic Expansion in Hospital Diagnostics Supports Buy Rating
- Masimo downgraded to Neutral from Buy at BTIG